Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM

Conditions

• Cytochrome P450 CYP2D6 Enzyme Deficiency
• Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
• Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant
• Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant
• Cytochrome P450 CYP2C9 Enzyme Deficiency
• Cytochrome P450 CYP2C19 Enzyme Deficiency
• Drug Metabolism, Poor, CYP2D6-RELATED
• Drug Metabolism, Poor, CYP2C19-RELATED
• CYP2D6 Polymorphism

Interventions

• GENETIC: Pharmacogenetic testing
• OTHER: Software-based drug & gene interaction risk analysis
• OTHER: MTM

Sponsor

Genelex Corporation